Ingen Receives Good Response From National Advertisment in COPD Digest

YUCAIPA, Calif., June 8, 2009 (GLOBE NEWSWIRE) -- Ingen Technologies, Inc. (Other OTC:IGNT.PK - News) a leading Medical Device Manufacturer focused in the $8 Billion global Respiratory Markets for the growing ageing population and emerging markets for Home (DME), Hospital and Aviation Industries announced today that the company has received an increase in Oxyview orders and telephone orders from COPD patients and new distributor inquiries from the advertisement in the COPD Digest.

In March-2009 Ingen signed an insertion order with COPD Digest to run a national advertisement for the new Oxyview. COPD Digest is published by the COPD Foundation, with the support of -- and contributions from -- organizations representing the entire COPD community. Chronic Obstructive Pulmonary Disease (COPD) affects over 600 million people worldwide. Oxyview provides these patients with the ability to assure oxygen flow and equipment function.

``Since the ad was issued last week with over 160,000 circulations, there has been an increase with on-line orders through our website and PayPal, as well as telephone orders. The patients and new potential distributors are very pleased with the new Oxyview product,'' stated Chris Wirth, Chief Operations Officer.

About Oxyview:

Oxyview is a proprietary medical device with U.S.-issued patents that stands alone in an increasing patient home oxygen therapy market while there are 23 million patients diagnosed with chronic obstructive pulmonary disease (COPD) in the United States, according to the World Health Organization, and another 12 million patients that are undiagnosed in the US. COPD is the fifth leading cause of death in the US and there are 600 million COPD patients worldwide where in most cases, COPD is either the first or second leading cause of death in other countries. The majority of COPD patients require continued home oxygen therapy, which includes all of the required equipment supplied by the home (DME) provider. With the new regulations for oxygen reimbursement in the US, the home (DME) providers need to cut costs to stay in business. Oxyview provides a substantial savings as a result of decreasing the number of service calls for the home (DME) provider. Oxyview is a pneumatic metering device that displays oxygen flow near the patient. The Oxyview flow meter easily and quickly installs on to the oxygen tubing nearest the patient where oxygen flow matters the most. Without the Oxyview, patients cannot confirm oxygen flow, and as a result there is an increase in anxiety and the patient calls the home (DME) provider with concerns. Oxyview also allows the home (DME) provider to trouble-shoot other equipment problems over the telephone which eliminates an on-site visit with the patient. More important, the Oxyview provides the patient with more assurance that they are receiving adequate and prescribed oxygen flow. The Oxyview cost less than a single service call.

http://www.ingen-tech.com

The Ingen Technologies, Inc. logo is available at http://www.globenewswire.com/newsroom/prs/?pkgid=2472

http://www.copddigest.org/about.php

Safe Harbor for Forward-Looking Statements: This news release includes forward-looking statements. While these statements are made to convey to the public the company's progress, business opportunities and growth prospects, readers are cautioned that such forward-looking statements represent management's opinion. Whereas management believes such representations to be true and accurate based on information and data available to the company at this time, actual results may differ materially from those described. The company's operations and business prospects are always subject to risk and uncertainties. Important factors that may cause actual results to differ are and will be set forth in the company's periodic filings with the U.S. Securities and Exchange Commission.